{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:46Z","timestamp":1753877686951,"version":"3.41.2"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Richter\u2019s syndrome (RS) is the next step in the progression of chronic lymphocytic leukemia (CLL) progression. It leads to reduced overall patient survival, the necessity of aggressive chemotherapy and a decline in the quality of life. The first line of RS treatment includes traditional chemotherapy such as rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. However, during the past decade, novel targeted agents added to the therapy dramatically changed the treatment outcome for patients with RS. In our case, we describe a patient with CLL that had progressed to RS and achieved complete remission that lasted &amp;gt; 15\u00a0months with venetoclax monotherapy.<\/jats:p>","DOI":"10.1093\/omcr\/omac111","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T09:07:34Z","timestamp":1666602454000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter\u2019s syndrome"],"prefix":"10.1093","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-2963","authenticated-orcid":false,"given":"Victoria Vladimirovna","family":"Tutaeva","sequence":"first","affiliation":[{"name":"The Main Military Clinical Hospital Named After N.N. Burdenko Department of Hematology, , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Romanovna","family":"Ovsannikova","sequence":"additional","affiliation":[{"name":"The Main Military Clinical Hospital Named After N.N. Burdenko Department of Pathology, , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Nikolaevich","family":"Bobin","sequence":"additional","affiliation":[{"name":"The Main Military Clinical Hospital Named After N.N. Burdenko Department of Pathology, , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurii Miroslavovich","family":"Kuchma","sequence":"additional","affiliation":[{"name":"The Main Military Clinical Hospital Named After N.N. Burdenko Department of Hematology, , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg Anatolievich","family":"Rukavitsin","sequence":"additional","affiliation":[{"name":"The Main Military Clinical Hospital Named After N.N. Burdenko Department of Hematology, , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","article-title":"Richter transformation in the era of novel agents","volume":"2018","author":"Ding","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"2023032712485870600_","article-title":"Richter\u2019s syndrome of the central nervous system diagnosed concurrently with chronic lymphocytic leukaemia: a case report and literature review","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"IJH09","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter\u2019s syndrome","volume":"7","author":"Allan","year":"2019","journal-title":"Int J Hematol Oncol"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/OTT.S187459","article-title":"Rapid and complete response to idelalisib in a case of Richter syndrome","volume":"12","author":"Bagacean","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2017.04.002","article-title":"Treatment of Del17p and\/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies","volume":"11","author":"Rafei","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/PPO.0000000000000535","article-title":"COVID-19 and chronic lymphocytic leukemia: where we stand now","volume":"27","author":"Chatzikonstantinou","year":"2021","journal-title":"Cancer J"},{"key":"2023032712485870600_","article-title":"Chronic lymphocytic leukemia treatment algorithm 2018. Blood","volume":"8","author":"Parikh","year":"2018","journal-title":"Cancer J"},{"key":"2023032712485870600_","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2022\/10\/omac111\/49630791\/omac111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2022\/10\/omac111\/49630791\/omac111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:27:54Z","timestamp":1701260874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omac111\/6769870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omac111","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,10,1]]},"article-number":"omac111"}}